0000000000947650

AUTHOR

D Santini

showing 4 related works from this author

Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense?

2013

Abstract: Objective: miRNAs are attractive molecules for cancer treatment, including colon rectal cancer (CRC). We investigate on the molecular mechanism by which miR-182 could regulate thrombospondin-1 (TSP-1) expression, a protein down-regulated in CRC and inversely correlated with tumor vascularity and metastasis. Background: MicroRNAs are small non-coding RNAs that regulate the expression of different genes, involved in cancer progression, angiogenesis and metastasis. miR-182, over-expressed in colorectal cancer (CRC), has like predictive target thrombospondin-1 (TSP-1), a protein inversely correlated with tumor vascularity and metastasis that results downregulated in different types of…

endocrine systemPathologymedicine.medical_specialtyColorectal cancerAngiogenesisSettore MED/06 - Oncologia MedicaClinical BiochemistryEnzyme-Linked Immunosorbent AssayBiologyReal-Time Polymerase Chain ReactionMetastasisThrombospondin 1immune system diseasesCell Line TumorDrug DiscoverymicroRNAThrombospondin 1Sense (molecular biology)medicineHumansPromoter Regions GeneticDNA PrimersPharmacologyBase SequencePharmacology. Therapyvirus diseasesCancerTransfectionOligonucleotides Antisensemedicine.diseaseMicroRNAsCancer researchanti-miR-182 colon cancer Egr-1 Sp-1 thrombospondin-1Molecular MedicineColorectal Neoplasms
researchProduct

Second-line treatment in exon 11-mutated GIST patients: Imatinib dose escalation or sunitinib? Retrospective analysis of a multi-institutional experi…

2014

10515 Background: Data from metastatic GIST patients harbouring exon 11 mutation who received a second line treatment with sunitinib or imatinib dose escalation were retrospectively analysed to compare survival. Methods: 123 exon 11 mutated advanced GIST patients were included. All patients progressed on imatinib 400 mg/die and received, on discretion of physician, a second line treatment with either imatinib (800 mg/die) or sunitinib (50 mg/die 4 weeks on/2 weeks of or 37.5 mg/day continuous daily dose). The type of exon 11 mutation was recorded (deletion versus others) and correlated with survival and response according to RECIST or CHOI criteria Results: 79 patients (64%) received a seco…

OncologyCancer Researchmedicine.medical_specialtySecond line treatmentGiSTSunitinibbusiness.industryImatinibMetastatic gistSurgeryExonOncologyInternal medicineDose escalationmedicineRetrospective analysisbusinessneoplasmsmedicine.drugJournal of Clinical Oncology
researchProduct

"Come un caduto cherubo". Annemarie Schwarzenbach in esilio volontario

2010

Settore L-LIN/13 - Letteratura TedescaSchwarzenbach Exilliteratur
researchProduct

Metastasi ossee

2010

Metastasi ossee
researchProduct